Now showing items 1-20 of 33102

    • Impact of the COVID-19 pandemic on patients with pre-existing anxiety disorders attending secondary care.

      Plunkett, R; Costello, S; McGovern, M; McDonald, C; Hallahan, B (2020-06-08)
      Objectives: To examine the psychological and social impact of the COVID-19 pandemic on patients with established anxiety disorders during a period of stringent mandated social restrictions. Methods: Semi-structured interviews were conducted with 30 individuals attending the Galway-Roscommon Mental Health Services with an International Classification of Diseases diagnosis of an anxiety disorder to determine the impact of the COVID-19 restrictions on anxiety and mood symptoms, social and occupational functioning and quality of life. Results: Twelve (40.0%) participants described COVID-19 restrictions as having a deleterious impact on their anxiety symptoms. Likert scale measurements noted that the greatest impact of COVID-19 related to social functioning (mean = 4.5, SD = 2.9), with a modest deleterious effect on anxiety symptoms noted (mean = 3.8, SD = 2.9). Clinician rated data noted that 8 (26.7%) participants had disimproved and 14 (46.7%) participants had improved since their previous clinical review, prior to commencement of COVID-19 restrictions. Conditions associated with no 'trigger', such as generalised anxiety disorder, demonstrated a non-significant increase in anxiety symptoms compared to conditions with a 'trigger', such as obsessive compulsive disorder. Psychiatric or physical comorbidity did not substantially impact on symptomatology secondary to COVID-19 mandated restrictions. Conclusions: The psychological and social impact of COVID-19 restrictions on individuals with pre-existing anxiety disorders has been modest with only minimal increases in symptomatology or social impairment noted.
    • Review of international ethics frameworks used in policy-making in the context of screening

      Health Information and Quality Authority (HIQA); Health Information and Quality Authority (HIQA) (Health Information and Quality Authority (HIQA), 2021-11-30)
    • Uropathogenic Biofilm-Forming Capabilities are not Predictable from Clinical Details or from Colonial Morphology.

      Whelan, Shane; O'Grady, Mary Claire; Corcoran, Dan; Finn, Karen; Lucey, Brigid (2020-04-30)
      Antibiotic resistance is increasing to an extent where efficacy is not guaranteed when treating infection. Biofilm formation has been shown to complicate treatment, whereby the formation of biofilm is associated with higher minimum inhibitory concentration values of antibiotic. The objective of the current paper was to determine whether biofilm formation is variable among uropathogenic Escherichia coli isolates and whether formation is associated with recurrent urinary tract infection (UTI), and whether it can be predicted by phenotypic appearance on culture medium A total of 62 E. coli isolates that were reported as the causative agent of UTI were studied (33 from patients denoted as having recurrent UTI and 29 from patients not specified as having recurrent UTI). The biofilm forming capability was determined using a standard microtitre plate method, using E. coli ATCC 25922 as the positive control. The majority of isolates (93.6%) were found to be biofilm formers, whereby 81% were denoted as strong or very strong producers of biofilm when compared to the positive control. Through the use of a Wilcox test, the difference in biofilm forming propensity between the two patient populations was found to not be statistically significant (p = 0.5). Furthermore, it was noted that colony morphology was not a reliable predictor of biofilm-forming propensity. The findings of this study indicate that biofilm formation is very common among uropathogens, and they suggest that the biofilm-forming capability might be considered when treating UTI. Clinical details indicating a recurrent infection were not predictors of biofilm formation.
    • COVID-19: Guidance for Hospitality Businesses [v2.0]

      Health Protection Surveillance Centre (Health Service Executive, 2021-11-17)
    • Covid-19 cases in Ireland: 14/10/21 [infographic]

      Health Protection Surveillance Centre (Health Service Executive, 2021-10-14)
    • Sanitise hands here [A4 poster]

      Health Protection Surveillance Centre; Government of Ireland; Health Service Executive (Health Service Executive, 2021-11)
    • NMIC Bulletin Sept 2020, Vol 26 No 2: Useful Medicines information resources for Healthcare Professionals

      National Medicines Information Centre (National Medicines Information Centre, St James's Hospital (SJ) Dublin 8, 2020-09)
      Bulletin
    • NMIC bulletin Dec 2020, Vol 26; No. 3: Drug Interactions (1) – General Principles

      National Medicines Information Centre (National Medicines Information Centre, St James's Hospital (SJ) Dublin 8, 2020-12)
      Bulletin
    • National SARS-CoV-2 Wastewater Surveillance Programme Week 43 2021 (24/10/2021—30/10/2021)

      Health Protection Surveillance Centre (Health Service Executive, 2021-11-03)
    • National SARS-CoV-2 Wastewater Surveillance Programme Week 42 2021 (17/10/2021—23/10/2021)

      Health Protection Surveillance Centre (Health Service Executive, 2021-10-28)
    • National SARS-CoV-2 Wastewater Surveillance Programme Week 39 2021 (26/09/2021—02/10/2021)

      Health Protection Surveillance Centre (Health Service Executive, 2021-10-08)
    • National SARS-CoV-2 Wastewater Surveillance Programme Week 41 2021 (10/10/2021—16/10/2021)

      Health Protection Surveillance Centre (Health Service Executive, 2021-10-20)
    • Future of Probiotics and Prebiotics and the Implications for Early Career Researchers.

      Spacova, Irina; Dodiya, Hemraj B; Happel, Anna-Ursula; Strain, Conall; Vandenheuvel, Dieter; Wang, Xuedan; Reid, Gregor (2020-06-24)
      The opportunities in the fields of probiotics and prebiotics to a great degree stem from what we can learn about how they influence the microbiota and interact with the host. We discuss recent insights, cutting-edge technologies and controversial results from the perspective of early career researchers innovating in these areas. This perspective emerged from the 2019 meeting of the International Scientific Association for Probiotics and Prebiotics - Student and Fellows Association (ISAPP-SFA). Probiotic and prebiotic research is being driven by genetic characterization and modification of strains, state-of-the-art in vitro, in vivo, and in silico techniques designed to uncover the effects of probiotics and prebiotics on their targets, and metabolomic tools to identify key molecules that mediate benefits on the host. These research tools offer unprecedented insights into the functionality of probiotics and prebiotics in the host ecosystem. Young scientists need to acquire these diverse toolsets, or form inter-connected teams to perform comprehensive experiments and systematic analysis of data. This will be critical to identify microbial structure and co-dependencies at body sites and determine how administered probiotic strains and prebiotic substances influence the host. This and other strategies proposed in this review will pave the way for translating the health benefits observed during research into real-life outcomes. Probiotic strains and prebiotic products can contribute greatly to the amelioration of global issues threatening society. The intent of this article is to provide an early career researcher's perspective on where the biggest opportunities lie to advance science and impact human health.
    • E-Cigarette-Only and Dual Use among Adolescents in Ireland: Emerging Behaviours with Different Risk Profiles.

      Health Service Executive (HSE); Bowe, Andrea K; Doyle, Frank; Stanistreet, Debbi; O'Connell, Emer; Durcan, Michéal; Major, Emmet; O'Donovan, Diarmuid; Kavanagh, Paul; Department of Public Health West, Health Service Executive, Merlin Park, Galway, Ireland. 2Department of Health Psychology, Royal College of Surgeons in Ireland, Dublin 2, Ireland. 3Department of Public Health and Epidemiology, Royal College of Surgeons in Ireland, Dublin 2, Ireland. 4Western Region Drug & Alcohol Task Force, Health Service Executive, Parkmore, Galway, Ireland. 5Western Region Drug & Alcohol Task Force, Galway Roscommon Education Training Board, Parkmore Galway, Ireland. 6School of Medicine, Dentistry and Biomedical Sciences, Centre for Public Health, Queens University, Belfast BT97BL, UK. 7Institution: Health Intelligence, Strategic Planning and Transformation, Health Service Executive, Dublin 1, Ireland. (MDPI, 2021-01-05)
    • Ordinary care in extraordinary times.

      Patel, S; Gannon, A; Cryan, M; McDonnell, N; Rafiq, S; Adamis, D; Dolan, C; McCarthy, G; Sligo/Leitrim Mental Health Services for Older Persons, Sligo, Republic of Ireland. 2School of Medicine, NUIG, Sligo, Republic of Ireland. PMID: 32912356 PMCID: PMC7522469 (Cambridge University Press, 2020-09-11)
    • Improving the quality of antibiotic prescribing through an educational intervention delivered through the out-of-hours general practice service in Ireland.

      O'Connor, Nuala; Breen, Roisin; Carton, Mícheál; Mc Grath, Ina; Deasy, Norma; Collins, Claire; Vellinga, Akke; Elmwood Medical Practice, Frankfield, Cork, Ireland. 2ICGP Irish College of General Practitioners, Dublin, Ireland. 3Antimicrobial Resistance and Infection Control Divison, HPSC Health Protection and Surveillance Centre, Dublin, Ireland. 4Quality Improvement Team, Health Service Executive, Dr Steevens Hospital, Dublin, Ireland. 5Therapy Unit, Cork Kerry Community Healthcare, Listowel, County Kerry, Ireland. 6Communications Division, Health Service Executive, Model Farm Road Business Park, Cork, Ireland. 7School of Medicine, National University of Ireland, Galway, Ireland. (Taylor & Francis Online, 2020-01-26)
    • Developing a complex intervention targeting antipsychotic prescribing to nursing home residents with dementia.

      Walsh, Kieran A; Byrne, Stephen; McSharry, Jenny; Browne, John; Irving, Kate; Hurley, Eimir; Rochford-Brennan, Helen; Geoghegan, Carmel; Presseau, Justin; Timmons, Suzanne; et al. (PMC, 2021-02-19)
      Background: Antipsychotics are commonly prescribed to people living with dementia in nursing home settings, despite strong guideline recommendations against their use except in limited circumstances. We aimed to transparently describe the development process for a complex intervention targeting appropriate requesting and prescribing of antipsychotics to nursing home residents with dementia in Ireland, by nurses and general practitioners (GPs) respectively. Methods: We report the development process for the 'Rationalising Antipsychotic Prescribing in Dementia' (RAPID) complex intervention, in accordance with the 'Guidance for reporting intervention development studies in health research' (GUIDED) checklist.  The UK Medical Research Council framework for developing and evaluating complex interventions guided our overall approach, incorporating evidence and theory into the intervention development process. To unpack the intervention development process in greater detail, we followed the Behaviour Change Wheel approach. Guided by our stakeholders, we conducted three sequential studies (systematic review and qualitative evidence synthesis, primary qualitative study and expert consensus study), to inform the intervention development. Results: The RAPID complex intervention was developed in collaboration with a broad range of stakeholders, including people living with dementia and family carers, between 2015 and 2017. The finalised RAPID complex intervention was comprised of the following three components; 1) Education and training sessions with nursing home staff; 2) Academic detailing with GPs; 3) Introduction of an assessment tool to the nursing home. Conclusions: This paper describes the steps used by the researchers to develop a complex intervention targeting antipsychotic prescribing to nursing home residents with dementia in Ireland, according to the GUIDED checklist. We found that the GUIDED checklist provided a useful way of reporting all elements in a cohesive manner and complemented the other tools and frameworks used. Transparency in the intervention development processes can help in the translation of evidence into practice.
    • Bringing Shame Out of the Shadows: Identifying Shame in Child Sexual Abuse Disclosure Processes and Implications for Psychotherapy.

      McElvaney, Rosaleen; Lateef, Rusan; Collin-Vézina, Delphine; Alaggia, Ramona; Simpson, Megan; Dublin City University, Dublin, Ireland. 2McGill University, Montreal, Canada. 3University of Toronto, Canada. 4Carlton University, Ottawa, Canada. (SAGE Journals, 2021-08-30)
    • New hepatitis C virus infection, re-infection and associated risk behaviour in male Irish prisoners: a cohort study, 2019.

      Crowley, Des; Avramovic, Gordana; Cullen, Walter; Farrell, Collette; Halpin, Anne; Keevans, Mary; Laird, Eamon; McHugh, Tina; McKiernan, Susan; Miggin, Sarah Jayne; et al. (BMC, 2021-06-08)